Kensey Nash Looking At Smaller Angio-Seal To Boost Market Share
This article was originally published in The Gray Sheet
Kensey Nash is predicting that the U.S. launch in January of a 6 Fr version of its Angio-Seal hemostatic puncture closure device will give the company a leg up on competitors Datascope (VasoSeal) and Perclose (ProStar and TechStar).
You may also be interested in...
St. Jude's $167 mil. cash acquisition of marketing and manufacturing rights to Kensey Nash's Angio-Seal hemostatic puncture closure device from Tyco International would "more than double" sales into the cardiology cath lab by St. Jude's Daig division and add 60 to its sales and marketing staff, the firm states.
Second read-out maintains 94% level of efficacy, with a very early signal that it could outperform Pfizer’s rival mRNA candidate in preventing severe cases.
The French major and Regeneron have racked up another indication for Dupixent with the blockbuster getting approval in Europe to treat children with severe eczema.